Transcriptomic analysis of the salivary gland of medicinal leech Hirudo nipponia
Lu Z, Shi P, You H, Liu Y, Chen S (2018) · PLoS ONE · n=0
Study Profile
- Design
- first sialotranscriptome (salivary-gland transcriptome) analysis of Hirudo nipponia using Illumina platform; 50,535 unigenes assembled and annotated; comparison to whole-transcriptome H. medicinalis data (Chongqing Academy of Chinese Materia Medica)
- Sample size (n)
- 0
- Intervention
- De novo Illumina sequencing and assembly of H. nipponia salivary-gland transcriptome
- Comparator
- Hirudo medicinalis whole-transcriptome reference
- Primary endpoint
- Identification of pharmacologically active candidate proteins in H. nipponia saliva
- Primary result
- 84.7 million clean reads assembled into 50,535 unigenes; more than 21 genes predicted to be involved in anti-coagulatory, antithrombotic, antibacterial, anti-inflammatory, and antitumor processes; first sialotranscriptome of H. nipponia opens biotechnology pipeline for Chinese medicinal-leech-derived drug discovery
- Follow-up duration
- Not applicable
- PMID
- 30339694
Key Findings
- First sialotranscriptome of H. nipponia — 50,535 unigenes
- More than 21 candidate pharmacologically active genes annotated
- Established methodological template for downstream H. nipponia drug-discovery work
- Underscores genomic distinctness of H. nipponia from H. medicinalis
- Foundational reference for Chinese medicinal-leech research community
Limitations
- Transcriptomic only — no protein-level validation
- Single biological sample / pool
- Annotation dependent on H. medicinalis reference at time of publication
- No clinical or therapeutic translation
- H. nipponia is not the K040187 device leech
Clinical Implications
Lu 2018 is the foundational sialotranscriptome reference for Hirudo nipponia and is cited throughout subsequent Chinese leech-pharmacology work (Shi 2023 recombinant hirudin, Kim 2023 spatial expression, Müller 2022 W. pigra cross-validation). For ASH, the paper supports the broader scientific narrative that Asian medicinal leech species harbor distinct pharmacology — without implying US K040187 clinical-practice change. Foundational research reference only.
Related Trials
Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification
Merlino G, Carbone S, Servillo G, Marletta DA (2020)
Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial
Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)
Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review
Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)
Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction
Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)